Endoscopic Surgery for Adrenal Tumors: Not Quicker, Not Cheaper, but Better for Patients

Publication
Article
OncologyONCOLOGY Vol 12 No 5
Volume 12
Issue 5

Dr. Charles H. Mayo performed one of the first successful operations to remove a tumor from the adrenal glands in 1927. After 187 days in the hospital, the patient recovered completely.

Dr. Charles H. Mayo performed one of the first successful operations to remove a tumor from the adrenal glands in 1927. After 187 days in the hospital, the patient recovered completely.

Today, this relatively rare surgery is commonly done with endoscopes, tiny tubes that enable the surgeon to view and work inside the body through small incisions.In a recent publication of Surgery, Mayo Clinic surgeons compare the results of adrenal surgery done endoscopically with the traditional “open” way on a matched set of 100 patients. Their findings mimic those of other comparison studies, showing that minimal access surgery results in shorter hospitalizations, fewer complications, and quicker return to normal but slightly higher operating room costs. Specific findings are on Table 1.

Dr. Geoffrey Thompson, the author of the report, says that minimal access surgery “is not necessarily easier, quicker, cheaper or safer. But it does have benefits for the patient and for society that are making it the procedure of choice for many purposes, including removal of adrenal tumors.”

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content